A mutation-independent CRISPR-Cas9–mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency

Ornithine transcarbamylase (OTC) deficiency is an X-linked urea cycle disorder associated with high mortality. Although a promising treatment for late-onset OTC deficiency, adeno-associated virus (AAV) neonatal gene therapy would only provide short-term therapeutic effects as the non-integrated geno...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lili, Yang, Yang, Breton, Camilo, Bell, Peter, Li, Mingyao, Zhang, Jia, Che, Yan, Saveliev, Alexei, He, Zhenning, White, John, Latshaw, Caitlin, Xu, Chenyu, McMenamin, Deirdre, Yu, Hongwei, Morizono, Hiroki, Batshaw, Mark L., Wilson, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015695/
https://www.ncbi.nlm.nih.gov/pubmed/32095520
http://dx.doi.org/10.1126/sciadv.aax5701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7015695/
https://www.ncbi.nlm.nih.gov/pubmed/32095520
http://dx.doi.org/10.1126/sciadv.aax5701

Ejemplares similares